We found that the tumor inhibitory effect of ACE was significantly greater than that of the ferroptosis-positive drugs sorafenib and artemisinin and even better than that of the clinical first-line drugs capecitabine and TAS-102, since ACE elevated Fe2+ and reduced PCBP2 and GPX4 significantly better than the other treatments did (Fig. 8a–d, Supplementary Fig. 15a–d). The gene discussed is ACE; the disease is neoplasm.